The significant reduction in net loss despite lower revenue suggests improved cost management. The pipeline advancements, particularly the positive ATI-052 data and upcoming catalysts in 2026, could drive investor interest. However, the declining revenue trend and cash burn of $47.1 million in 2025 warrant monitoring. Traders should focus on upcoming data readouts in 2026 as potential value inflection points.
Price Chart
Executive Summary
Aclaris Therapeutics reported financial results for Q4 and full year 2025, showing a significant reduction in net loss year-over-year despite lower revenue. The company highlighted positive interim Phase 1a trial results for its ATI-052 bispecific antibody, initiation of Phase 1b trials in atopic dermatitis and asthma, and advancement of its ITK inhibitor programs. With $151.4 million in cash, Aclaris expects funding into the second half of 2028.
Key Financial Metrics
Key Facts
- Net loss decreased to $19.8 million in Q4 2025 from $96.6 million in Q4 2024, and full-year net loss decreased to $64.9 million from $132.1 million
- Total revenue declined to $1.3 million in Q4 2025 from $9.2 million in Q4 2024, primarily due to a milestone achieved in 2024 under the Eli Lilly agreement
- Cash, cash equivalents, and marketable securities were $151.4 million as of December 31, 2025, down from $203.9 million in 2024
- Positive interim Phase 1a SAD/MAD trial results for ATI-052 showed favorable safety, dose-proportional PK, and robust target engagement
- Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma are underway with top-line results expected in second half of 2026
- IND application for lead ITK inhibitor ATI-9494 expected in second half of 2026
- ATI-2138 demonstrated potential best-in-class hair regrowth in murine alopecia model with 93% mean regrowth vs 78% for ritlecitinib
Financial Impact
Revenue decreased by $7.9 million YoY in Q4 and $10.9 million for full year 2025, while net loss improved by $76.8 million YoY in Q4 and $67.2 million for full year
Risk Factors
- Revenue decline of 85.9% YoY in Q4 and 58.3% for full year 2025
- Cash position decreased by $52.5 million from 2024 to 2025
- High R&D expenses increased to $52.6 million in 2025 from $33.6 million in 2024
- Reliance on successful clinical trial outcomes for future value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-020070 |
| Document: acrs-20260226x8k.htm | 0001104659-26-020070 |
| Document: 0001104659-26-020070-index-headers.html | 0001104659-26-020070 |
| Document: 0001104659-26-020070-index.html | 0001104659-26-020070 |
| Document: 0001104659-26-020070.txt | 0001104659-26-020070 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $3.78 | awaiting T+5 | — | $3.70 (−2.12%) |
Oct 27, 2026 today | Press Release | $3.89 | awaiting T+5 | — | $3.70 (−4.88%) |
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.70 (−36.64%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.70 (−39.24%) |
Apr 28, 2026 26w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.70 (−12.32%) |
Apr 28, 2026 26w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.70 (−12.32%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.70 (−18.68%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.70 (+5.11%) |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | $3.70 (+0.27%) |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | $3.70 (+1.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers